OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Microbiology and Infection is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Cefiderocol for resistant Gram negatives: linking in vitro activity with clinical effectiveness	262
‘Scope and aims of ESCMID guidelines’ by Scudeller et al.	206
Re: Diagnostic limitations and challenges in current clinical guidelines and potential application of metagenomic sequencing to manage pulmonary invasive fungal infections in patients with haematologi	152
Re: ‘The relative effectiveness of a high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccines in older adults in France: a retrospective cohort study during the 20	147
Re: ‘Association between pertactin-producing Bordetella pertussis and fulminant pertussis in infants: a multicentre study in France, 2008–2019’ by Leroux et al.	139
Primary antifungal prophylaxis after haematopoietic stem cell transplantation: will the search for perfection become the enemy of good?	128
Which trial do we need? Doxycycline in combination with ceftriaxone for the treatment of community-acquired pneumonia	122
Outside Front Cover	120
COVID-19 in special populations	113
Re: what is the role of epidemiological investigations in human Campylobacter outbreaks in the One Health and whole-genome sequencing era in Denmark?	112
Has the COVID-19 pandemic wiped out the seasonality of outpatient antibiotic use and influenza activity? A time-series analysis from 2014 to 2021	110
Re: ‘Dosing and route of administration of clindamycin given in combination with rifampicin’ by Magreault et al.	110
The diagnostic value of serum Borrelia burgdorferi antibodies and seroconversion after Lyme neuroborreliosis, a nationwide observational study	107
Should multiplex PCR testing be integrated into antimicrobial stewardship programs for paediatric community-acquired pneumonia in the emergency department?	98
Assessment of BIV1-CovIran inactivated vaccine–elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern	95
Limitations of genomic surveillance: a Clostridioides difficile case study in the Netherlands	91
Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab	89
Acute cough in outpatients: what causes it, how long does it last, and how severe is it for different viruses and bacteria?	86
How to: Diagnose inborn errors of intrinsic and innate immunity to viral, bacterial, mycobacterial, and fungal infections	83
TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate	83
Risk of major structural birth defects following repeat mRNA COVID-19 vaccination in the first trimester: a population-based cohort study	82
Delayed intestinal adenovirus response to intravenous brincidofovir in paediatric allogeneic stem cell transplant recipients displaying rapid clearance of the virus from peripheral blood	78
Large language models for antibiotic prescribing—moving the needle from ‘parlour trick’ to practical tool	77
A randomized trial of simultaneous versus sequential pneumococcal vaccination in elderly	76
European society of clinical microbiology and infectious diseases guidelines for antimicrobial stewardship in emergency departments (endorsed by European association of hospital pharmacists)	72

What is the evidence base of used aggregated antibiotic resistance percentages to change empirical antibiotic treatment? A scoping review	71
Optimising the management of invasive candidiasis	71
Expected phenotypes and expert rules are important complements to antimicrobial susceptibility testing	68
Measuring the impact of hospitalization for infectious diseases on the quality of life of older patients in four European countries: the AEQUI longitudinal matched cohort study (2020–2023)	68
The interplay between Epstein-Barr virus and cytomegalovirus reactivation following allogeneic haematopoietic cell transplantation in the era of primary cytomegalovirus prophylaxis	66
Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models	65
The importance of patient information and informed consent for unlicensed phage therapy	64
Pathogen and host determinants of extrapulmonary tuberculosis among 1035 patients in Frankfurt am Main, Germany, 2008–2023	63
Myxovirus resistance protein A for discriminating between viral and bacterial lower respiratory tract infections in children – The TREND study	62
Exploring the limits of interferon-γ releasing assay screening in large-scale populations	62
A phase Ib, placebo-controlled randomized clinical trial of the Ebolavirus DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSVΔG-ZEBOV-GP-primed voluntee	62
‘Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward’ – author's response	61
Antimicrobial susceptibility of Mycobacterium abscessus and treatment of pulmonary and extra-pulmonary infections	61
Optimizing antifungal therapies for Candida infections: evidence, resistance, and emerging approaches	58
Acquired fluconazole resistance and genetic clustering in Diutina (Candida) catenulata from clinical samples	57
‘Early antifungal prophylaxis fails to prevent influenza-associated pulmonary aspergillosis in the ICU’– Author’s reply	56
Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation	56
Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis	56
Re: Compromised access to antibiotics: addressing paediatric challenges in availability and responsible use	55
Respiratory syncytial virus in adults with comorbidities: an update on epidemiology, vaccines, and treatments	52
Effects of azithromycin and doxycycline on the vaginal microbiota of women with urogenital Chlamydia trachomatis infection: a substudy of the Chlazidoxy randomized controlled trial	51
Re: ‘Heightened incidence of adverse events associated with a live attenuated varicella vaccine strain that lacks critical genetic polymorphisms in ORF62’ by Kim et al.	51
Developing tailored dosing recommendations for ciprofloxacin in critically ill children using a population approach based on total and unbound concentrations	50
A comparative evaluation of commercial boric acid containers for preserving microorganisms in urine specimens	50